Panbela Opens Enrollment In UK And Germany For Aspire Trial In Pancreatic Cancer, All Countries/Regions In The Aspire Trial Are Now Open And Actively Enrolling
Portfolio Pulse from Happy Mohamed
Panbela Therapeutics, Inc. (NASDAQ:PBLA) has opened enrollment in the UK and Germany for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. The company plans to have all sites open for enrollment within the next couple of months, and then towards the interim data analysis in early 2024. There are approximately 95 sites planned for throughout the United States, Europe, Australia, and South Korea.
July 24, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Panbela's announcement of the expansion of its ASPIRE clinical trial to the UK and Germany could potentially boost investor confidence in the company's progress and future prospects.
The expansion of the ASPIRE clinical trial to the UK and Germany signifies progress in Panbela's research and development efforts. This could potentially attract more investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100